mRNA profilin identifies low levels of phosphatases dual-specific phosphatase-7 (DUSP7) and cell division cycle-25B (CDC25B) in patients with early arthritis
Loading...
Download
Official URL
Full text at PDC
Publication date
2017
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Oxford University Press
Citation
P Castro-Sánchez, R Ramirez-Munoz, A Lamana, A Ortiz, I González-Álvaro, P Roda-Navarro, mRNA profilin identifies low levels of phosphatases dual-specific phosphatase-7 (DUSP7) and cell division cycle-25B (CDC25B) in patients with early arthritis, Clinical and Experimental Immunology, Volume 189, Issue 1, July 2017, Pages 113–119, https://doi.org/10.1111/cei.12953
Abstract
Phosphotyrosine phosphatases (PTPs) control phosphorylation levels and, consequently, regulate the output of intracellular signalling networks in health and disease. Despite the high number of PTPs expressed in CD4 T cells and their involvement in autoimmunity, information about the expression profile of PTPs in these cells has not been obtained in patients diagnosed with autoimmune diseases. Here, we compare the expression profile of PTPs in CD4 T cells of healthy volunteers and patients submitted to an early arthritis clinic, due to suspicion of rheumatoid arthritis, an autoimmune disease mediated by CD4 T cells. We found lower transcript levels of the mitogen-activated protein kinase (MAPK) phosphatase dual-specific phosphatase-7 (DUSP7) and the cell division cycle-25B (CDC25B) in T cells of patients. While the low expression level of DUSP7 was restricted to patients with positive rheumatoid factor and anti-citrullinated protein antibodies, the altered expression of CDC25B correlated with the activity of the disease. Low levels of CDC25B might contribute to the progression of the autoimmune arthritis and/or might be consequence of the inflammatory environment in the active disease. The possible role of DUSP7 and CDC25B as biomarkers of the disease in clinical protocols is discussed.
Description
This work was supported by funds of the Spanish Ministry of Economy and Competitiveness (MINECO) (SAF2012-33218 and SAF2016-75656-P) and the European Union (FP7-PEOPLE-2012-CIG) to P. R.-N. These projects support P. C.-S. and R. R.-M. The PEARL study is supported by PI14/00442 to IG-A and the work of A. L. was supported by PIE13/00041, both grants from the MINECO (‘Instituto de Salud Carlos III’), co-funded by ‘Fondo Europeo de Desarrollo Regional’ (FEDER). A. L. was co-funded by SER (Sociedad Española de Reumatología) to A. O.